Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Gilead Sciences, Inc.

< Previous 1 2 3 4 5 6 7 8 9 Next >
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Provides Update on Phase 3 EVOKE-01 Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
From Gilead Sciences, Inc.
Via Business Wire
Tickers CGEN GILD
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite and Arcellx Announce Expansion in Strategic Partnership
From Gilead Sciences, Inc.
Via Business Wire
Tickers ACLX GILD
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Third Quarter 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD RCUS
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
From Gilead Sciences, Inc.
Via Business Wire
Tickers ASMB GILD
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.